EUVIMEDEUVIMED entdecken
Crossref

Use of proton pump inhibitors and risk of severe COVID‐19: A case–control study in United States Medicare beneficiaries

Andrew D Mosholder, Hector S Izurieta, Rongmei Zhang, Shanlai Shangguan iD, Yun Lu, Sandia Akhtar, Michael Wernecke, Jiwei He, Yoganand Chillarige, Yuhui Feng, Armen Avagyan, Kira Leishear und 4 weitere

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.4614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Andrew D Mosholder und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, COVID-19, Medicare, Hospitalization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: This study was funded in full by the U.S. Food and Drug Administration, through an interagency agreement with the Centers for Medicare & Medicaid Services. The….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Concerns have been raised regarding proton pump inhibitor (PPI) use and risk of severe coronavirus disease 2019 (COVID‐19). Observational studies have yielded heterogeneous results and were subject to important methodological limitations.

Aims

To examine the association between the receipt of PPIs and risk of COVID‐19 hospitalizations and severe in‐hospital outcomes or death.

Methods

Case–control study among Medicare fee‐for‐service beneficiaries 66+ years old with gastroesophageal reflux disorder (GERD). Within this population, we identified cases by an incident hospital discharge diagnosis of COVID‐19 from April 1 to December 11, 2020, using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) U07.1, and randomly selected up to 10 controls per case, matched on date and neighborhood. We defined PPI use as a prescription providing ≥15 days of supply in the 30 days before admission, with H2‐receptor antagonist (H2RA) use as the reference to account for indication. We analyzed uncomplicated hospitalizations and hospitalizations with severe outcomes (intensive/coronary care unit admission, invasive mechanical ventilation, or death), estimating odds ratios (ORs), and 95% confidence intervals (CIs) with multinomial conditional logistic regression adjusted for demographics, comorbidities, chronic medications, and health care utilization.

Results

We matched 25,867 uncomplicated and 12,954 severe hospitalized COVID‐19 cases to 146,972 and 73,104 controls, respectively. Cases tended to be older and have more comorbidities. Relative to H2RA use, we found no association of PPI use with uncomplicated COVID‐19 hospitalization (OR 0.99, 95% CI 0.93–1.06) or severe COVID‐19 hospitalization (OR 1.00, 95% CI 0.91–1.10).

Conclusions

Relative to H2RA use, PPI use was not associated with uncomplicated or severe COVID‐19 hospitalizations among Medicare beneficiaries with GERD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsCOVID-19MedicareHospitalizationGastroesophageal RefluxHumansUnited StatesAgedCase-Control StudiesMaleFemaleAged, 80 and overSeverity of Illness IndexHistamine H2 AntagonistsSARS-CoV-2

Stichwörter der Autor:innen

COVID‐19GERDH2RAPPI

Substanzen

Proton Pump InhibitorsHistamine H2 Antagonists

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Acumen, LLC, Burlingame, California, USA.
  • Department of Economics, Stanford University, Palo Alto, California, USA.
  • Centers for Medicare and Medicaid Services, Washington, DC, USA.

ORCID-Profile: Shanlai Shangguan

Förderung

  • This study was funded in full by the U.S. Food and Drug Administration, through an interagency agreement with the Centers for Medicare & Medicaid Services. The…

Zitieren

APA

Mosholder, A. D., Izurieta, H. S., Zhang, R., Shangguan, S., Lu, Y., Akhtar, S., Wernecke, M., He, J., Chillarige, Y., Feng, Y., Avagyan, A., Leishear, K., Forshee, R. A., MaCurdy, T. E., Kelman, J. A., & Graham, D. J. (2024). Use of proton pump inhibitors and risk of severe COVID‐19: A case–control study in United States Medicare beneficiaries. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4614

Vancouver

Mosholder AD, Izurieta HS, Zhang R, Shangguan S, Lu Y, Akhtar S, et al. Use of proton pump inhibitors and risk of severe COVID‐19: A case–control study in United States Medicare beneficiaries. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4614

BibTeX
@article{Mosholder2024,
  author = {Mosholder, Andrew D and Izurieta, Hector S and Zhang, Rongmei and Shangguan, Shanlai and Lu, Yun and Akhtar, Sandia and Wernecke, Michael and He, Jiwei and Chillarige, Yoganand and Feng, Yuhui and Avagyan, Armen and Leishear, Kira and Forshee, Richard A and MaCurdy, Thomas E and Kelman, Jeffrey A and Graham, David J},
  title = {Use of proton pump inhibitors and risk of severe COVID‐19: A case–control study in United States Medicare beneficiaries},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.4614}
}
Kostenlos starten →